reference/9961023

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9961023

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1809
issn	0923-7534
issueIdentifier	9
pageRange	1804-1809
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	1804
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d5c87b62e73e1894009649fdf5e08458
bibliographicCitation	Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010 Sep;21(9):1804–9. PMID: 20150572; PMCID: PMC2924992.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ecdc4861b3800a93355d3eca04965f9a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5027ded763853b449e1a91c315e179eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f19249af81337717f5929f0e4b87d056 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_56f005a1db766f4d14455b2f11d460d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f8ac84151a2518ee192c3dcda026c97 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9168140b0c88c37e29b141b1032097cb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a76af2b0e97702af2cb32da4cd940c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d423e621af6e6cd27db61164acae1bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_debfecd62d0d883b85df5938bd831e1f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42a6b77368998a1117ae50406710cb3a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0bc2ae82f6345bd112c61c04be82196d
date	201009
identifier	https://doi.org/10.1093/annonc/mdq020 https://pubmed.ncbi.nlm.nih.gov/20150572 https://pubmed.ncbi.nlm.nih.gov/PMC2924992
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846 https://portal.issn.org/resource/ISSN/0923-7534
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
discusses	http://id.nlm.nih.gov/mesh/M0443627 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0016932 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M000754277
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D008175Q000401 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D002289Q000401 http://id.nlm.nih.gov/mesh/D002289Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D000068258 http://id.nlm.nih.gov/mesh/D009364Q000188 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D018196Q000473 http://id.nlm.nih.gov/mesh/D018196Q000188 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D018196Q000401 http://id.nlm.nih.gov/mesh/D009364Q000473 http://id.nlm.nih.gov/mesh/D009364Q000401 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D010919
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129281950 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128334455 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127377427 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136058681

Predicate

Subject

isDiscussedBy

Total number of triples: 75.